Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02446912
Registration number
NCT02446912
Ethics application status
Date submitted
14/05/2015
Date registered
18/05/2015
Date last updated
12/01/2023
Titles & IDs
Public title
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Query!
Scientific title
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Query!
Secondary ID [1]
0
0
D3461C00005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Active Systemic Lupus Erythematosus
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Anifrolumab
Treatment: Drugs - Placebo
Experimental: Anifrolumab - higher dose - Anifrolumab
Placebo comparator: Placebo - Placebo
Experimental: Anifrolumab - lower dose - Anifrolumab
Treatment: Other: Anifrolumab
Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
Treatment: Drugs: Placebo
Placebo IV administration every 4 weeks from Week 0 to Week 48
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index =4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)
Query!
Assessment method [1]
0
0
SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of =4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of =0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.
Query!
Timepoint [1]
0
0
Week 52
Query!
Secondary outcome [1]
0
0
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of =4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)
Query!
Assessment method [1]
0
0
SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of =4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of =0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.
Query!
Timepoint [1]
0
0
Week 52
Query!
Secondary outcome [2]
0
0
Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of =7.5 mg/Day in the Sub-group of Participants With Baseline OCS =10 mg/Day (Original Analysis With Restricted Medication Rules)
Query!
Assessment method [2]
0
0
Maintained OCS reduction was defined by meeting all the following criteria:
Achieve an OCS dose of =7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose =7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.
Query!
Timepoint [2]
0
0
Week 52
Query!
Secondary outcome [3]
0
0
Number of Participants With a =50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score =10 (Original Analysis With Restricted Medication Rules)
Query!
Assessment method [3]
0
0
50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria:
Achieve =50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment.
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of =4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)
Query!
Assessment method [4]
0
0
SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of =4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of =0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold.
Query!
Timepoint [4]
0
0
Week 24
Query!
Secondary outcome [5]
0
0
Annualized Flare Rate
Query!
Assessment method [5]
0
0
A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.
Query!
Timepoint [5]
0
0
Baseline to Week 52
Query!
Secondary outcome [6]
0
0
Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)
Query!
Assessment method [6]
0
0
A BICLA responder was achieved if all of the following criteria was met:
All criteria related to SRI(4) (please see primary endpoint) plus:
Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.
Query!
Timepoint [6]
0
0
Week 52
Query!
Secondary outcome [7]
0
0
Number of Participants Reporting One or More Adverse Events (AE)
Query!
Assessment method [7]
0
0
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.
Query!
Timepoint [7]
0
0
Baseline to End of Trial (Maximum of 60 weeks)
Query!
Secondary outcome [8]
0
0
Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)
Query!
Assessment method [8]
0
0
An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death).
AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Query!
Timepoint [8]
0
0
Baseline to End of Trial (Maximum of 60 weeks)
Query!
Secondary outcome [9]
0
0
Number of Participants With Markedly Abnormal Vital Signs
Query!
Assessment method [9]
0
0
Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.
Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Query!
Timepoint [9]
0
0
Baseline to End of Trial (Maximum of 60 weeks)
Query!
Secondary outcome [10]
0
0
Number of Participants With Markedly Abnormal Physical Examinations
Query!
Assessment method [10]
0
0
Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported.
Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Query!
Timepoint [10]
0
0
Baseline to End of Trial (Maximum of 60 weeks)
Query!
Secondary outcome [11]
0
0
Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores
Query!
Assessment method [11]
0
0
ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant.
Query!
Timepoint [11]
0
0
Baseline to Week 52
Query!
Secondary outcome [12]
0
0
Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index
Query!
Assessment method [12]
0
0
The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories.
Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Query!
Timepoint [12]
0
0
Baseline to End of Trial (Maximum of 60 weeks)
Query!
Secondary outcome [13]
0
0
Number of Participants With Markedly Abnormal Laboratory Tests
Query!
Assessment method [13]
0
0
Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Query!
Timepoint [13]
0
0
Baseline to End of Trial (Maximum of 60 weeks)
Query!
Secondary outcome [14]
0
0
Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)
Query!
Assessment method [14]
0
0
The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered "yes" at any time during the treatment period (Baseline to Week 52) to one of the 10 categories:
Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide
Query!
Timepoint [14]
0
0
Baseline to Week 52
Query!
Secondary outcome [15]
0
0
Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score
Query!
Assessment method [15]
0
0
PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms.
Query!
Timepoint [15]
0
0
Baseline to Week 52
Query!
Eligibility
Key inclusion criteria
1. Aged 18 through 70 years at the time of screening
2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982 revised criteria =24 weeks prior to signing the Informed Consent form (ICF)
3. Currently receiving at least 1 of the following:
1. Where prednisone is the single standard of care medication (ie, the subject is not concurrently receiving any medication listed in inclusion criterion 3(c)), a dose of oral prednisone =7.5 mg/day but =40 mg/day (or prednisone equivalent) for a minimum of 8 weeks prior to Day 1. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation.
2. Where prednisone is not the single standard of care medication (ie, the subject is concurrently receiving at least one medication listed in inclusion criterion 3(c)), a dose of oral prednisone (=40 mg/day) (or prednisone equivalent) for a minimum of 2 weeks prior to signing of the ICF. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation.
3. Any of the following medications administered for a minimum of 12 weeks prior to signing the informed consent, and at a stable dose for a minimum of 8 weeks prior to signing the informed consent through Day 1:
(i) Azathioprine =200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil =2 g/day or mycophenolic acid =1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate =25 mg/week (v) Mizoribine =150 mg/day
4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at least 1 of which must be:
1. Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay (IFA) at the central laboratory with titre =1:80; OR
2. Anti-dsDNA antibodies at screening elevated to above normal (including indeterminante), as per the central laboratory; OR
3. Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the central laboratory.
5. At Screening, Disease Activity Adjudication Group confirmation of:
SLEDAI-2K Criteria: SLEDAI-2K score =6 points and "Clinical" SLEDAI-2K score =4 points. The "Clinical" SLEDAI-2K is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or laboratory results including immunologic measures.
6. Must not have active or latent TB on either chest radiograph or by quantiferon gold test
7. Day 1 "Clinical" SLEDAI-2K score =4 points
8. OCS dose stable for at least 2 weeks prior to randomisation
9. Stable SLE SOC treatment at the time of randomisation
10. Women of child-bearing potential must have a negative serum ß-hCG test and negative urine pregnancy test at randomisation (Day 1) prior to administration of investigational product
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Receipt of any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater
2. Receipt of any of the following:
(a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to Day 1
3. History of, or current diagnosis of, a clinically significant non SLE-related vasculitis syndrome.
4. Active severe or unstable neuropsychiatric SLE
5. Active severe SLE-driven renal disease
6. Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE or SSc.
7. History of, or current, inflammatory joint or skin disease other than SLE
8. History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than 2 weeks within the last 24 weeks prior to signing the ICF
9. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation
10. Confirmed positive test for hepatitis B or hepatitis C
11. Any severe herpes infection at any time prior to Week 0 (Day 1)
12. Opportunistic infection requiring hospitalisation or intravenous antimicrobial treatment within 3 years prior to randomization
13. History of cancer, apart from:
1. Squamous or basal cell carcinoma of the skin that has been successfully treated
2. Cervical cancer in situ that has been successfully treated
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/06/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/07/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
460
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Fitzroy
Query!
Recruitment hospital [2]
0
0
Research Site - Kogarah
Query!
Recruitment hospital [3]
0
0
Research Site - St Leonards
Query!
Recruitment postcode(s) [1]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2065 - St Leonards
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Hampshire
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oklahoma
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
South Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Tennessee
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Wisconsin
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Cordoba
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
San Miguel de Tucuman
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Belo Horizonte
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Juiz de Fora
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Porto Alegre
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Salvador
Query!
Country [28]
0
0
Chile
Query!
State/province [28]
0
0
Osorno
Query!
Country [29]
0
0
Chile
Query!
State/province [29]
0
0
Santiago
Query!
Country [30]
0
0
Chile
Query!
State/province [30]
0
0
Vina del Mar
Query!
Country [31]
0
0
Colombia
Query!
State/province [31]
0
0
Armenia
Query!
Country [32]
0
0
Colombia
Query!
State/province [32]
0
0
Barranquilla
Query!
Country [33]
0
0
Colombia
Query!
State/province [33]
0
0
Bogota
Query!
Country [34]
0
0
Colombia
Query!
State/province [34]
0
0
Bucaramanga
Query!
Country [35]
0
0
Colombia
Query!
State/province [35]
0
0
Medellin
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Berlin
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Dessau-RoBlau
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Frankfurt am Main
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Göttingen
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Kirchheim
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Köln
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Budapest
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Debrecen
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Szeged
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Zalaegerszeg
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Haifa
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Jerusalem
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Kfar Saba
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Petach-Tikva
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Tel Aviv
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Milano
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Padova
Query!
Country [53]
0
0
Korea, Republic of
Query!
State/province [53]
0
0
Daejeon
Query!
Country [54]
0
0
Korea, Republic of
Query!
State/province [54]
0
0
Gwangju
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Jeonju-si
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Seoul
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Suwon-si
Query!
Country [58]
0
0
New Zealand
Query!
State/province [58]
0
0
Hamilton
Query!
Country [59]
0
0
New Zealand
Query!
State/province [59]
0
0
Wellington
Query!
Country [60]
0
0
Peru
Query!
State/province [60]
0
0
Arequipa
Query!
Country [61]
0
0
Peru
Query!
State/province [61]
0
0
Lima
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Bialystok
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Bydgoszcz
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Elblag
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Kraków
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Lublin
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Nadarzyn
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Poznan
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Sosnowiec
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Starachowice
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Szczecin
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Ustron
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Warszawa
Query!
Country [74]
0
0
Romania
Query!
State/province [74]
0
0
Brasov
Query!
Country [75]
0
0
Romania
Query!
State/province [75]
0
0
Bucharest
Query!
Country [76]
0
0
Romania
Query!
State/province [76]
0
0
Bucuresti
Query!
Country [77]
0
0
Romania
Query!
State/province [77]
0
0
Cluj Napoca
Query!
Country [78]
0
0
Romania
Query!
State/province [78]
0
0
Galati
Query!
Country [79]
0
0
Romania
Query!
State/province [79]
0
0
Tg Mures
Query!
Country [80]
0
0
Taiwan
Query!
State/province [80]
0
0
Kaohsiung Hsien
Query!
Country [81]
0
0
Taiwan
Query!
State/province [81]
0
0
Taichung
Query!
Country [82]
0
0
Taiwan
Query!
State/province [82]
0
0
Taipei
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Kiev
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Kyiv
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Lviv
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
Ternopil
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Uzhgorod
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Vinnytsia
Query!
Country [89]
0
0
Ukraine
Query!
State/province [89]
0
0
Zaporizhzhia
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Brighton
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Doncaster
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Leeds
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
London
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Manchester
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Romford
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Staffordshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
PRA Health Sciences
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
Query!
Trial website
https://clinicaltrials.gov/study/NCT02446912
Query!
Trial related presentations / publications
Bruce IN, van Vollenhoven RF, Morand EF, Furie RA, Manzi S, White WB, Abreu G, Tummala R. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). 2023 Apr 3;62(4):1526-1534. doi: 10.1093/rheumatology/keac491. Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, Merrill JT, Puzio P, Maho E, Kleoudis C, Albulescu M, Hultquist M, Tummala R. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 Jul;81(7):962-969. doi: 10.1136/annrheumdis-2021-221847. Epub 2022 May 17. Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25. Loncharich MF, Anderson CW. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. ACR Open Rheumatol. 2022 Jun;4(6):486-491. doi: 10.1002/acr2.11414. Epub 2022 Feb 14. Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022 May 5;61(5):1900-1910. doi: 10.1093/rheumatology/keab704. Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, Abreu G, Pineda L, Tummala R. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul;30(8):1254-1263. doi: 10.1177/09612033211014267. Epub 2021 May 12. Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, Pineda L, Tummala R. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. Arthritis Rheumatol. 2021 Nov;73(11):2059-2068. doi: 10.1002/art.41778. Epub 2021 Sep 22. Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Herbert Hutman, MD
Query!
Address
0
0
Medical Science Director
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/12/NCT02446912/Prot_002.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/12/NCT02446912/SAP_003.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02446912
Download to PDF